Empagliflozin significantly attenuates QTc prolongation in rats due to sotalol (original) (raw)
Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers
Patrice Jaillon
Clinical Pharmacology and Therapeutics, 1992
View PDFchevron_right
Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines
Karel Van Ammel
British Journal of Pharmacology, 2008
View PDFchevron_right
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology
Charles Antzelevitch
Cardiovascular Research, 2000
View PDFchevron_right
Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs
t p
View PDFchevron_right
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
serge bottari
Cardiovascular Diabetology, 2013
View PDFchevron_right
Restoring depressed HERG K+ channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits
Zhiguo Wang, PhD, FAHA, FESC
American Journal of Physiology-Heart and Circulatory Physiology, 2006
View PDFchevron_right
The Combined Use of Ibutilide as an Active Control With Intensive Electrocardiographic Sampling and Signal Averaging as a Sensitive Method to Assess the Effects of Tadalafil on the Human QT Interval
Charles M Beasley, Jr., M.D.
Journal of the American College of Cardiology, 2005
View PDFchevron_right
The Time Course of New T-Wave ECG Descriptors Following Single- and Double-Dose Administration of Sotalol in Healthy Subjects
Fabio Badilini
2010
View PDFchevron_right
Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit
Ard Teisman
Journal of Pharmacological and Toxicological Methods, 2005
View PDFchevron_right
Prolonged Tp-e Interval, Tp-e/QT Ratio and Tp-e/QTc Ratio in Patients with Type 2 Diabetes Mellitus
Mehmet Uzun
Endocrinology and metabolism (Seoul, Korea), 2015
View PDFchevron_right
QTc prolongation and diabetes therapies
Neil Munro
Diabetic Medicine, 2012
View PDFchevron_right
Evaluation of the Effect of 5 QT‐Positive Drugs on the JTpeak Interval — An Analysis of ECGs From the IQ‐CSRC Study
Thuan Pham
The Journal of Clinical Pharmacology, 2019
View PDFchevron_right
Modulation of the QT interval duration in hypertension with antihypertensive treatment
Peter Kruzliak
Hypertension research : official journal of the Japanese Society of Hypertension, 2015
View PDFchevron_right
Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes
Jean-Marie Poirier
Journal of the American College of Cardiology, 1995
View PDFchevron_right
Drug-induced QT prolongation when QT interval is measured in each of the 12 ECG leads in men and women in a thorough QT study
Deepak Manohar
Journal of Electrocardiology, 2014
View PDFchevron_right
Concentration/response relations for the multiple antiarrhythmic actions of sotalol
Jean Barbey
The American Journal of Cardiology, 1990
View PDFchevron_right
Discrepant Regulation of QT (QTc) Interval Duration by Calcium Channel Blockade and Angiotensin Converting Enzyme Inhibition in Experimental Hypertension
Jan Kyselovic
Basic & Clinical Pharmacology & Toxicology, 2012
View PDFchevron_right
Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem?
Charles Antzelevitch
Journal of Electrocardiology, 2004
View PDFchevron_right
The relationship between QTc interval and cardiac autonomic neuropathy in diabetes mellitus
Ali Hekmatnia
Biochemistry of Diabetes and Atherosclerosis, 2003
View PDFchevron_right
Literature review and pilot studies of the effect of qt correction formulas on reported β2-agonist-induced QTc prolongation
Milos Milic
Clinical Therapeutics, 2006
View PDFchevron_right
The Challenges of Predicting Drug-Induced QTc Prolongation in Humans
Michael K Pugsley
Toxicological Sciences, 2022
View PDFchevron_right
Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents
Balvinder Singh
American Journal of Cardiology, 1993
View PDFchevron_right
The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias
David J Gallacher
British Journal of Pharmacology, 2010
View PDFchevron_right
The Prophylactic Effects of Metoprolol, Diltiazem, and Pilocarpine on Hypoglycemia-Induced Prolongation of QT Interval
Ismail Aslan
Cureus, 2021
View PDFchevron_right
Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation
Marek Malik
Drug Safety, 2016
View PDFchevron_right
Non-antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries
Ulf Bergman
British Journal of Clinical Pharmacology, 2002
View PDFchevron_right
Glucose and blood pressure lowering effects of Pycnogenol® are inefficient to prevent prolongation of QT interval in experimental diabetic cardiomyopathy
Stanislava Jankyova, Peter Musil, Jan Kyselovic
Pathology - Research and Practice, 2012
View PDFchevron_right
Drug-Induced QT Interval Prolongation: Mechanisms, Risk Factors, Genetics and Clinical Management
Sule Kalkan
The Journal of Basic and Clinical Health Sciences
View PDFchevron_right
Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design
Daisuke Kutsuzawa
Diabetes Therapy, 2020
View PDFchevron_right
Investigation role of ondansetron on long QT interval among non-cardiac patients
Shahrouz Tabrizi
Annals of Medicine and Surgery, 2021
View PDFchevron_right
Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3
Uwe Kirchhefer
Cardiovascular Research, 2010
View PDFchevron_right